Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy

Mattia Galli¹, Domenico D’Amario¹*†, Felicita Andreotti¹, Italo Porto², Rocco Vergallo¹, Mario Sabatelli³, Stefano Lancellotti⁴, Emilia Meleo³, Raimondo De Cristofaro⁴ and Filippo Crea¹

¹Dipartimento di Scienze Cardiovascolari e Toraciche, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00167, Rome, Italy; ²Cardiovascular Disease Unit, Ospedale Policlinico San Martino, IRCCS, University of Genoa, Genoa, Italy; ³NeuroMuscular Omnicentre (NEMO), Serena Onlus Foundation-Pol. Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Catholic University of the Sacred Heart School of Medicine, Rome, Italy; ⁴Institute of Internal Medicine & Geriatrics, Haemostasis and Thrombosis Center, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Area of Hematology, Catholic University of the Sacred Heart School of Medicine, Rome, Italy

Abstract

Extensive data support the safety of direct oral anticoagulants compared with vitamin K antagonists in patients with non-valvular atrial fibrillation, leading to a significantly increase in the use of these compounds in clinical practice. However, there is no compelling evidence supporting the use of direct oral anticoagulant in individuals who are intubated or have a percutaneous endoscopic gastrostomy (PEG): patients with several co-morbidities are underrepresented in clinical trials, so the best long-term strategy for anticoagulation is difficult to ascertain. The aim of the present report was to evaluate the safety and efficacy of edoxaban administered via PEG in a patient with heart failure and a history of atrial fibrillation affected by amyotrophic lateral sclerosis (ALS). A 71-year-old man with atrial fibrillation, advanced ALS, type II diabetes mellitus, and hypertension presented to the emergency department with dyspnoea and tachycardia. Because vitamin K antagonist and rivaroxaban 15 mg were dropped because of difficult international normalized ratio control (time in therapeutic range <30%) and severe haematuria, respectively, edoxaban 30 mg (crushed pill) daily was administered based on the patient’s weight of 58 kg. Mean edoxaban plasma concentration–time profiles were measured, as anti-Xa activity, 2 h before and at 2, 6, and 22 h after drug administration and then compared with the pharmacokinetic profile of edoxaban 30 mg in healthy subjects. An additional testing of steady-state peak plasma concentration of edoxaban after 10 days and a 30 day follow-up were evaluated. The values of the pharmacokinetic parameters, analysed with a non-compartmental analysis by PKSolver module, showed that Cmax and AUC0–τ were only slightly higher than those observed in healthy subjects, while the half-life and observed clearance were significantly longer and lower, respectively, than in normal subjects. Steady-state peak plasma concentration of edoxaban was very similar to the levels reported in healthy subjects, and neither relevant bleeding nor thromboembolic event was reported at a 30 day follow-up. These results support safe and effective anticoagulation with edoxaban 30 mg but suggest caution with the use of full dose of edoxaban (60 mg daily) in this kind of patients. We report, for the first time, a safe and effective anticoagulation based on the administration of edoxaban 30 mg daily through PEG in a patient with advanced ALS, acute respiratory, and heart failure, presenting with Takotsubo syndrome and atrial fibrillation.

Keywords  Takotsubo syndrome; Edoxaban; Amyotrophic lateral sclerosis; Atrial fibrillation; Percutaneous endoscopic gastrostomy

Received: 19 October 2018; Accepted: 22 February 2019

*Correspondence to: Domenico D’Amario, Dipartimento di Scienze Cardiovascolari e Toraciche, Fondazione Policlinico Universitario ‘A. Gemelli’ IRCCS, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00167 Rome, Italy. Email: domenico.damario@gmail.com

†These authors equally contributed to this work.
Introduction

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, characterized by both upper and lower motor neuron dysfunction. Most patients die of respiratory complications 3–5 years after its onset. Patients treated with invasive ventilation through tracheostomy show an average further survival of 2 years. Difficult swallowing is another frequent complication often requiring percutaneous endoscopic gastrostomy (PEG) in order to provide proper nutritional support and minimize the risk of aspiration pneumonia. Although autonomic dysfunction is not considered a main feature of the disease, sudden hypertensive or hypotensive crises, followed by circulatory collapse, have been described, especially in the advanced stages of ALS. Recent publications have reported that heart diseases, including atrial fibrillation and heart failure, are common in ALS patients and are independently associated with reduced survival.

Takotsubo syndrome (TTS), also known as stress-induced cardiomyopathy, represents an acute heart failure syndrome characterized by ST-segment elevation and reversible left ventricular regional wall motion abnormalities (typically involving the apex). The precise pathogenesis of TTS remains unknown; a neurogenic origin with excessive catecholamine production causing microvascular spasm and direct cardiotoxicity may be involved. Several recent publications suggest that TTS, presenting with acute exacerbation of dyspnoea and chest discomfort, is relatively common in ALS patients, particularly in the advanced stages of ALS.

Additionally, atrial fibrillation (AF) is a common complication of both TTS and ALS, and the use of anticoagulation in such fragile patients may be particularly challenging.

Case report

A 71-year-old man with advanced ALS, type II diabetes mellitus, and hypertension presented to the emergency department with dyspnoea and tachycardia. The family reported a history of paroxysmal atrial fibrillation treated with subcutaneous low molecular weight heparin (4000 IU twice daily). Vitamin K antagonist and rivaroxaban 15 mg had been tried and then suspended because of difficult international normalized ratio control (time in therapeutic range <30%) and severe haematuria, respectively. The patient was bedridden and had a PEG—placed 2 years before—and a permanent urinary catheter. On admission, blood pressure was 80/60 mmHg, heart rate was 118 b.p.m., oxygen saturation was 84%, and body temperature was 38.1 °C. Blood tests showed 19.95 × 10^9/L white blood cells, C-reactive protein 249.9 mg/dL, and creatinine 0.28 mg/dL. The calculated estimated glomerular filtration rate was 138 mL/min/1.73 m^2. On admission, high-sensitivity troponin I levels were 2.874 ng/mL (normal range <0.040 ng/mL). Chest X-rays documented bilateral interstitial pulmonary oedema and pleural effusion. Antibiotic therapy with levofloxacin and piperacillin–tazobactam was empirically started. However, the 12-lead electrocardiogram showed anterior ST-segment elevation with diffuse repolarization abnormalities (Figure 1), and ultra-sensitive serum troponin I concentrations were elevated (peak 3.589 ng/mL). Urgent coronary angiography revealed no significant epicardial coronary artery obstructions, while ventricular angiography showed apical ballooning typical of TTS (Figure 2). Because of respiratory failure and severe hypotension, the patient was treated in the coronary care unit with inotropes and orotracheal intubation. Echocardiography showed a left ventricular ejection fraction of 30%, with
akinesia of the mid and apical segments. The patient required prolonged respiratory support (5 days) followed by tracheostomy. AF at high ventricular rate occurred after coronary angiography. A rate control strategy was initiated along with low molecular weight heparin 4000 IU twice daily (CHA2DS2-VASc score: 4). Nevertheless, a long-term oral anticoagulation strategy was needed in order to avoid chronic subcutaneous administration of heparin by the caregivers. Edoxaban 30 mg (crushed pill) daily was administered based on the patient’s weight of 58 kg.

Mean edoxaban plasma concentration–time profiles were measured as anti-Xa activity using the STA®-Liquid Anti-Xa assays and STA®-Edoxaban Calibrator (0–500 ng/mL) on a STA Compact Max® instrument (all from Diagnostica Stago, Asnières-sur-Seine, France). Edoxaban concentration was measured 2 h before and 2, 6, and 22 h after drug administration and compared with the pharmacokinetic profile of edoxaban 30 mg in healthy subjects (Figure 3).10 An additional blood sample 2 h after edoxaban administration was performed 10 days later to assess the steady-state peak plasma concentration of edoxaban. In our patient, edoxaban peak plasma concentrations, both after the first administration and at steady state, were similar to the values reported for healthy subjects treated with edoxaban 30 mg (Figure 3).10–14 However, the values of the pharmacokinetic parameters, analysed with a non-compartmental analysis by PKSolver module of the Excel software, showed that $C_{\text{max}}$ and AUC$_{0-\infty}$ were only slightly higher than those observed in healthy subjects,15 while the half-life and observed clearance were significantly longer and lower, respectively, than in normal subjects15 (Table 1). These results suggest great caution with the use of full dose of edoxaban (60 mg daily)

in this kind of patients, as supra-normal edoxaban concentrations might occur even in the presence of apparently normal kidney and liver function.

After 7 days, echocardiography showed improved ejection fraction (45%). At the 30 day follow-up, only minimal and self-limiting haematuria (Bleeding Academic Research Consortium Type 1) was reported related to replacement of the urinary catheter, not requiring drug suspension; no thromboembolic event occurred.

Discussion

The use of direct oral anticoagulants has not been described in patients with PEG, and the pharmacokinetics of these agents in such patients is unknown. Our report is the first to describe the successful administration of edoxaban 30 mg daily (crushed and diluted in 10 mL of saline solution) through a PEG in a patient with advanced ALS, tracheostomy, atrial fibrillation, and acute heart failure (Figure 4). Edoxaban was ultimately chosen, given its good safety profile and its balanced renal and biliary clearance (respectively 50 and 50%).10,12,13 This precaution was considered necessary because the Cockcroft–Gault estimate of renal function (based on serum creatinine, sex, body weight, and age) might have been distorted by the extremely low muscle mass of this totally bedridden patient with advanced ALS.14

We support the evaluation of the effect on anticoagulation by using a calibrated quantitative anti-factor Xa assay,
Table 1  Pharmacokinetic parameters of the patient analysed with a non-compartmental analysis by PKSolver module of the Excel software

| Parameter                  | Unit     | Value        |
|----------------------------|----------|--------------|
| λ2                         | 1/h      | 0.062954806  |
| t1/2                       | h        | 11.01023459  |
| tmax                       | h        | 2            |
| Cmax                       | ng/mL    | 178          |
| tlag                       | h        | 0            |
| Clast obs/Cmax             |          | 0.241573034  |
| AUC0→t                     | ng/mL·h  | 2338         |
| AUC0→∞obs                  | ng/mL·h  | 3021.029666  |
| AUC0→t/0→∞obs              |          | 0.773908322  |
| AUMC0→∞obs                 | ng/mL·h² | 45 848.23581 |
| MRT0→∞obs                  | h        | 15.17636067  |
| Vz/Feobs                   | (mg)/(ng/mL) | 0.15773838  |
| Clearanceobs               | (mg)/(ng/mL)/h | 0.009930389 |

Cmax and AUC0→t were only slightly higher than those observed in healthy subjects,\(^{15}\) while the half-life and observed clearance were considerably longer and lower, respectively, than in normal subjects.

Figure 4  The edoxaban plasma concentration after a single dose of edoxaban 30 mg in a patient with percutaneous endoscopic gastrostomy was compared with that reported by Parasrampuria and Truitt\(^{10}\) in healthy subjects. Steady-state concentration after 10 days in the patient with percutaneous endoscopic gastrostomy was also assessed and compared with that reported by Chung et al.\(^{11}\) in healthy subjects after 28 days (steady state is reached on average after 4 days\(^{10}\)).
which may help to inform clinical decisions in particular situations.

Although further data are needed to confirm that edoxaban administration via PEG is safe and effective, this case supports its feasibility and potential favourable profile to treat fragile, complex, co-morbid patients with AF, acute heart failure, advanced ALS, and PEG.

Conflict of interest

F.A. is a consultant or speaker for Actelion, Amgen, Bayer, BMS/Pfizer, Boehringer Ingelheim, and Daiichi Sankyo. The other authors do not have any conflicts of interest to declare.

References

1. Foster LA, Salajegehe MK. Motor neuron disease: pathophysiology, diagnosis, and management. Am J Med 2019; 132: 32–37.
2. Niedermeyer S, Murn M, Choi PJ. Respiratory failure in amyotrophic lateral sclerosis. Chest 2019; 155: 401–408.
3. Shimizu T, Hayashi H, Kato S, Hayashi M, Tanabe H, Oda M. Circulatory collapse and sudden death in respiratory-dependent amyotrophic lateral sclerosis. J Neurol Sci 1994; 124: 45–55.
4. Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, Hauw JJ, Meininger V. Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 2008; 9: 59–62.
5. Mandrioli J, Ferri L, Fasano A, Zucchi E, Fini N, Moglia C, Lunetta C, Marinou K, Ticozzi N, Drago Ferrante G, Scialo C, Soraru G, Trojci F, Conte A, Falzone YM, Tortelli R, Russo M, Sansona VA, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Monsurro MR, Sabatelli M, Chio A, Riva N, Logroscino G, Messina S, Calvo A. Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 2018; 25: 861–868.
6. Pelliccia F, Kaski JC, Crea F, Camici PG. Pathophysiology of Takotsubo syndrome. Circulation 2017; 135: 2426–2441.
7. Lyon AR, Bosson E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E. Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2016; 18: 8–27.
8. Choi SJ, Hong YH, Shin JY, Yoon BN, Sohn SY, Park CS, Sung JJ. Takotsubo cardiomyopathy in amyotrophic lateral sclerosis. J Neurol Sci 2017; 375: 289–293.
9. Peters S. Tako tsubo cardiomyopathy in respiratory stress syndrome in amyotrophic lateral sclerosis. Int J Cardiol 2014; 177: 187.
10. Parsasampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2016; 55: 641–655.
11. Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, Lee TH, Chen SA. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011; 105: 535–544.
12. Barhala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos 2012; 40: 2250–2255.
13. Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014; 35: 1844–1855.
14. Baxmann AC, Ahmed MS, Marques NC, Menon VB, Pereira AB, Kirsztajn GM, Heilberg IP. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol 2008; 3: 348–354.
15. Hanada K, Matsumoto S-I, Shibata S, Matsubara H, Tsukimura Y, Takahashi H. A quantitative LC/MSMS method for determination of edoxaban, a Xa inhibitor and its pharmacokinetic application in patients after total knee arthroplasty. Biomed Chromatogr 2018; 32: e4213.